What kind of communications approach can turn the launch of a new report or new clinical data into a real campaign of advocacy?
It’s a more important question than people realise.
Marketers get all worked up about the possibility of using PR because they’ve got some new clinical paper being published or they’ve commissioned some expert to do a big review of their disease area.
There were an estimated 25,000 raucous people at the regional music festival Groovin’ the Moo in Maitland on the Anzac Weekend.
I was there with my family and the crowd were remarkably well behaved. One bloke – clearly unfamiliar with old codgers like me so close to the front at such an event - exclaimed “A DZ dad!” and kissed me on the cheek as DZ Deathrays were warming up.
Security and police were everywhere (especially later in the day) and they mingled comfortably with the crowd, keeping an eye on unruly behaviour.
For all the talk about the importance of a “positive corporate reputation”, there is surprisingly little written about what tangible actions you should take to build one. What specific themes should be the focus for Australian medical and pharmaceutical companies that aspire to lift their organisational reputation?
The recently announced $1 billion Government spend on breakthrough hepatitis C treatments is a major milestone that gives hope to the 230,000 Australia’s living with the disease. The aim is to eradicate hepatitis C within a generation in what has been billed as the biggest PBS announcement since the HPV National Immunization Program.